Abstract
The pharmacological treatment options for obesity are currently very limited but the prevalence of the disease is increasing rapidly. Obesity has many serious sequelae, the most common of which is type-2-diabetes. The benefits of weight loss on health are established but the major impediment to weight loss treatments is maintenance of weight lost over the long term. The reduced- or post-obese individual undergoes physiological changes that are geared towards energy storage and weight regain. One of the physiological changes is a reduced capacity to oxidise fatty acids pushing them through pathways of triacylglycerol synthesis. In this review, some of the past drug treatments aimed at increasing energy expenditure, such as dinitrophenol and ephedrine, are discussed. Current, or nearly current therapies such as sibutramine and rimonabant are also discussed in the context of increased energy expenditure. The main part of the review focuses on future prospects with discussion around a selection of targets with potential in energy expenditure that lie in pathways with AMP-kinase at their centre and ending at the mitochondrion.
Keywords: obesity, energy expenditure, type-2-diabetes
Current Drug Targets
Title: Treating Obesity: Pharmacology of Energy Expenditure
Volume: 5 Issue: 3
Author(s): John C. Clapham
Affiliation:
Keywords: obesity, energy expenditure, type-2-diabetes
Abstract: The pharmacological treatment options for obesity are currently very limited but the prevalence of the disease is increasing rapidly. Obesity has many serious sequelae, the most common of which is type-2-diabetes. The benefits of weight loss on health are established but the major impediment to weight loss treatments is maintenance of weight lost over the long term. The reduced- or post-obese individual undergoes physiological changes that are geared towards energy storage and weight regain. One of the physiological changes is a reduced capacity to oxidise fatty acids pushing them through pathways of triacylglycerol synthesis. In this review, some of the past drug treatments aimed at increasing energy expenditure, such as dinitrophenol and ephedrine, are discussed. Current, or nearly current therapies such as sibutramine and rimonabant are also discussed in the context of increased energy expenditure. The main part of the review focuses on future prospects with discussion around a selection of targets with potential in energy expenditure that lie in pathways with AMP-kinase at their centre and ending at the mitochondrion.
Export Options
About this article
Cite this article as:
Clapham C. John, Treating Obesity: Pharmacology of Energy Expenditure, Current Drug Targets 2004; 5 (3) . https://dx.doi.org/10.2174/1389450043490451
DOI https://dx.doi.org/10.2174/1389450043490451 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Curcumin: A Natural Product for Diabetes and its Complications
Current Topics in Medicinal Chemistry Multiple Pregnancies After ART and How to Minimize their Occurrence
Current Women`s Health Reviews Anti-Vascular Endothelial Growth Factor Treatment in Retinal Vein Occlusions
Current Drug Therapy Oxidative Stress in Alzheimer Patients in Different Stages of the Disease
Current Medicinal Chemistry Insoluble Solids in Brazilian and Floridian Acai (Euterpe oleraceae Mart.)
The Natural Products Journal Endothelial Dysfunction and Coronary Artery Spasm
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial: Paving the Way for Improved Antiplatelet Therapy
Current Pharmaceutical Design Treatment of IgG4-Related Disease
Current Immunology Reviews (Discontinued) Editorial (Thematic Issue: Cognitive Dysfunction in Major Depressive Disorder - Pathophysiology, Clinical Implications and Treatment Opportunities)
CNS & Neurological Disorders - Drug Targets Metabolic Syndrome - Risk Factors for Atherosclerosis and Diabetes
Current Diabetes Reviews Collateral Circulation in Chronic Total Occlusions – an interventional perspective
Current Cardiology Reviews Alterations in Glucose Metabolism in Alzheimer's Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Diabetic Papillopathy: Current and New Treatment Options
Current Diabetes Reviews Cross-linked Mucoadhesive Microspheres based on Anionic Heteropolysaccharide for Nasal Delivery of Felodipine: Optimization and in vitro Evaluation
Drug Delivery Letters The Effects of Smoking Cessation on Diabetes Mellitus Patients
Current Diabetes Reviews Management of the Metabolic Syndrome as a Strategy for Preventing the Macrovascular Complications of Type 2 Diabetes: Controversial Issues
Current Diabetes Reviews Biochemical Markers of Renal Function
Current Medicinal Chemistry Hypertension in Pregnancy: A Review of Current Guidelines
Current Women`s Health Reviews Diuretics: From Classical Carbonic Anhydrase Inhibitors to Novel Applications of the Sulfonamides
Current Pharmaceutical Design Gender Differences in the Treatment of Ischemic Heart Disease
Current Pharmaceutical Design